Loading…
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-53M | $-48M | $-28M | -27.9% | - | 75.4% |
| 2024 | $0M | $-29M | $-28M | $-19M | -29.0% | - | 44.6% |
| 2023 | $0M | $-20M | $-19M | $-18M | -173.3% | - | 5.4% |
| 2022 | $0M | $-18M | $-18M | $-18M | -85.8% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 18.13 | 20.09 | 28.59 | 53.35 |
| Research And Development | - | 12.03 | 13.62 | 17.21 | 29.79 |
| Selling General And Administration | - | 6.22 | 6.73 | 11.38 | 23.56 |
| Total Expenses | - | 18.13 | 20.09 | 28.59 | 53.35 |
| Operating Income | - | -18.13 | -20.09 | -28.59 | -53.35 |
| Total Operating Income As Reported | - | -18.13 | -20.09 | -28.59 | -51.97 |
| EBITDA | - | -18.12 | -19.91 | -28.56 | -53.29 |
| Normalized EBITDA | - | -18.12 | -19.91 | -28.56 | -54.66 |
| EBIT | - | -18.13 | -20.09 | -28.59 | -53.35 |
| Interest Income | - | 0.07 | 1.06 | 1.07 | 3.72 |
| Interest Expense | 0.02 | - | - | - | - |
| Net Interest Income | - | 0.07 | 1.06 | 1.07 | 3.72 |
| Other Income Expense | - | - | - | - | 1.37 |
| Interest Income Non Operating | - | 0.07 | 1.06 | 1.07 | 3.72 |
| Interest Expense Non Operating | 0.02 | - | - | - | - |
| Net Non Operating Interest Income Expense | - | 0.07 | 1.06 | 1.07 | 3.72 |
| Pretax Income | - | -18.05 | -19.03 | -27.52 | -48.26 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -18.05 | -19.03 | -27.52 | -48.26 |
| Net Income From Continuing And Discontinued Operation | - | -18.05 | -19.03 | -27.52 | -48.26 |
| Net Income From Continuing Operation Net Minority Interest | - | -18.05 | -19.03 | -27.52 | -48.26 |
| Net Income | - | -18.05 | -19.03 | -27.52 | -48.26 |
| Net Income Common Stockholders | - | -18.05 | -19.03 | -27.52 | -48.26 |
| Net Income Including Noncontrolling Interests | - | -18.05 | -19.03 | -27.52 | -48.26 |
| Normalized Income | - | -18.05 | -19.03 | -27.52 | -49.63 |
| Diluted NI Availto Com Stockholders | - | -18.05 | -19.03 | -27.52 | -48.26 |
| Basic Average Shares | 3.03 | 4.22 | 6.03 | 23.71 | - |
| Diluted Average Shares | 3.03 | 4.22 | 6.03 | 23.71 | - |
| Reconciled Depreciation | - | 0.01 | 0.18 | 0.03 | 0.06 |
| Total Unusual Items | - | - | - | 0 | 1.37 |
| Total Unusual Items Excluding Goodwill | - | - | - | 0 | 1.37 |
| Special Income Charges | - | - | - | 0 | 1.37 |
| Restructuring And Mergern Acquisition | - | - | - | 0 | -1.37 |
| Other Operating Expenses | -3.10 | -0.12 | -0.26 | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc.this co. | IKT | $219M | -4.54 | 1.27 | -27.9% | -1.50 |
| LENZ Therapeutics, Inc. | LENZ | $226M | - | 0.79 | -28.9% | - |
| Fulcrum Therapeutics, Inc. | FULC | $225M | - | 0.64 | -21.5% | - |
| Foghorn Therapeutics Inc. | FHTX | $220M | -2.96 | -2.02 | 68.5% | -2.28 |
| Voyager Therapeutics, Inc. | VYGR |
| - |
| - |
| - |
| - |
| $219M |
| -1.83 |
| 1.12 |
| -61.1% |
| -1.49 |
| Utah Medical Products, Inc. | UTMD | $216M | 19.17 | 1.82 | 9.5% | 9.09 |
| Pro-Dex, Inc. | PDEX | $214M | 23.83 | 5.84 | 24.5% | 16.29 |
| Keros Therapeutics, Inc. | KROS | $213M | 2.45 | 0.70 | 28.7% | -0.83 |
| RxSight, Inc. | RXST | $211M | -5.42 | 0.77 | -14.1% | -5.68 |
| Peer Median | - | 0.31 | 0.78 | -2.3% | -1.16 | |